 |
| Research article summary (published 30 Dec 2005): |
Lifetime health consequences and cost-effectiveness of rosiglitazone in combination with metformin for the treatment of type 2 diabetes in Spain.
Full Abstract
OBJECTIVE:
To assess the lifetime diabetes health consequences and cost-effectiveness in Spain of rosiglitazone in combination with metformin for the treatment of type 2 diabetes in overweight and obese patients failing to maintain glycaemic control with metformin monotherapy compared with conventional care of metformin in combination with either sulfonylureas or bedtime insulin.
RESEARCH DESIGN AND METHODS:
The Diabetes Decision Analysis of Cost--Type 2 was adapted for clinical practice and healthcare funding in Spain, and was calibrated with Spanish epidemiological, healthcare resource use and cost data, taking the perspective of the Spanish National Health System. The model simulates lifetime treatment histories, complications and consequences of type 2 diabetes, and associated health outcomes and costs for age and sex-matched cohorts of 1000 overweight and obese patients. The primary health outcome measures compared are glycaemic control, time to insulin, incidence and prevalence of coronary heart disease, stroke, clinical nephropathy, ulceration and amputation, and severe visual loss, and incremental life-years and quality-adjusted life-years (QALYs).
RESULTS:
Rosiglitazone in combination with metformin produces better glycaemic control than conventional care of metformin in combination with either sulfonylureas or bedtime insulin in most patients, and extends the viability of combination therapy by between 6 and 13 years before requiring insulin. Rosiglitazone patients have a longer life expectancy, gaining between 106 and 175 additional life-years per 1000 patients, experience fewer episodes of coronary disease and clinical nephropathy, and live for longer periods free of complications. The improvements in morbidity and mortality are projected to yield between 134 and 238 additional QALY per 1000 patients over their lifetime. Discounted incremental cost-effectiveness ratios range from euro 9406 to euro 23,514 per QALY gained.
CONCLUSION:
The model predicts that rosiglitazone in combination with metformin is a cost-effective intervention for the treatment of both overweight and obese patients with type 2 diabetes when compared with conventional care in Spain.
Learn Faster Today Improve your study skills
Author information
Author/s: Shearer, Arran T (AT); Bagust, Adrian (A); Ampudia-Blasco, F Javier (FJ); Martínez-Lage Alvarez, Belén (B); Pérez Escolano, Isabel (I); París, Gonzalo (G);
Affiliation: York Health Economics Consortium, University of York, Heslington, UK. as57(-atsign-)york.ac.uk
Journal and publication information
Publication Type: Journal Article; Research Support, Non-U.S. Gov't; Review
Journal: PharmacoEconomics (Pharmacoeconomics), published in New Zealand. (Language: eng)
Reference: 2006-; vol 24 Suppl 1 (issue ) : pp 49-59
Dates: Created 2006/06/27; Completed 2006/07/20; Revised 2006/11/15;
PMID: 16800162, status: MEDLINE (last retrieval date: 12/26/2008)
Sourced from the National Library of Medicine. Abstract text and other information may be subject to copyright.
Comments and Corrections
CommentIn: Pharmacoeconomics. 2006;24(9):927-9; author reply 929-35. (PMID: 16942126)
External Links for this article (including full text providers, if available):
Click Electronic Full-text Provider Links to see options for finding the electronic full text links to this article. Note there may be a subscription or fee required for access to the full text. See our FAQ for information on finding FREE full text articles.
This article may also be located in paper journal collections available in many libraries. Use the Journal and Publication Information above to find the full article.
MeSH headings (categories)
This article was linked to the MESH Headings shown below.
|
|
Related articles
These are the highest related articles currently in the database:
- Optimizing antidiabetic treatment options for patients with type 2 diabetes mellitus and cardiovascular comorbidities.
30 Jan 2008 - A comparison of select cardiovascular outcomes by antidiabetic prescription drug classes used to treat type 2 diabetes among Military Health System beneficiaries, fiscal year 2003-2006. 29 Apr 2008
- Cost-effectiveness analysis of thiazolidinediones in uncontrolled type 2 diabetic patients receiving sulfonylureas and metformin in Thailand. 28 Feb 2008
- Weight loss in obese type 2 diabetic patients on an intensive therapeutic programme: Importance of an initial short hospitalization period.
27 Oct 2007 - Mealtime 50/50 basal + prandial insulin analogue mixture with a basal insulin analogue, both plus metformin, in the achievement of target HbA1c and pre- and postprandial blood glucose levels in patients with type 2 diabetes: a multinational, 24-week, randomized, open-label, parallel-group comparison. 30 Oct 2007
- Comparison of biphasic insulin aspart 30 given three times daily or twice daily in combination with metformin versus oral antidiabetic drugs alone in patients with poorly controlled type 2 diabetes: a 16-week, randomized, open-label, parallel-group trial conducted in russia. 30 Oct 2007
- Clinical decisions. Management of type 2 diabetes. 15 Jan 2008
- The effect of metformin treatment on VEGF and PAI-1 levels in obese type 2 diabetic patients. 19 Mar 2008
- Rosiglitazone therapy improves insulin resistance parameters in overweight and obese diabetic patients intolerant to metformin. 8 Mar 2008
- Comparison of the effects of pioglitazone and metformin on hepatic and extra-hepatic insulin action in people with type 2 diabetes.
Oct 2007
Related Article Map
10/1/2007
4/29/2008
Higher Relevance Score (21)
Lower Relevance Score (17)
Legend: - FREE Full text Article. - Abstract only. - Title only. More help.
See a large map of 100+ related articles.